Jubilant Pharmova Limited (JUBLPHARMA) — key facts
NSE-listed · Healthcare. Data as of 11 Nov 2026 (IST) from InvestSights.
Last close: ₹968.4 (+2.7% day change)
Key ratios
- P/E ratio
- 38.5
- P/B ratio
- 1.82
- ROE (%)
- 5.62
- ROCE (%)
- 6.31
- Debt/Equity
- 0.51
- Dividend yield (%)
- 0.61
- Market cap (₹ Cr)
- 15,340.29
Forensic checks
Piotroski F-Score: 4/9 · Altman Z-Score: 6.33 · Beneish M-Score: -2.49
InvestSights quality score
58.1/100 — Average (descriptive data-driven composite; not a recommendation)
Latest earnings call (Q4 FY26)
AI summary: The single most important signal from this concall is the acceleration in Spokane Line 3 commercialisation, now expected to reach peak revenue of $80 mn–$90 mn one-and-a-half to two years ahead of the original plan, with $60–$80 mn in FY2027 tech-transfer revenues already contracted across 10+ products (80% complex biologics). This, combined with the management's first…
Full analysis on InvestSights
InvestSights is an analytics platform and is not SEBI-registered as a Research Analyst or Investment Adviser. All figures are educational, descriptive data — not investment advice. Consult a SEBI-registered adviser before investing.